Omada Health's GLP-1 Behavior Change Companion Programs Help Drive Lasting, Long-Term Weight Loss

Impact · against what's priced in

Omada Health's clinical data demonstrates that its companion program significantly improves both GLP-1 medication persistence (67% vs ~48%) and total weight loss (18.4% vs 11.9%). The ability to drive superior real-world outcomes and expand into direct prescribing increases the company's value proposition to employers and its potential revenue per member.

OMDA+0.60

No priced-in read yet